Unigene Laboratories

Unigene Laboratories was an American biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey.^[1][2]

Unigene Laboratories

Company type	Public
Traded as	OTC Pink No Information: /quote UGNEQ
Industry	Biotechnology
Founded	1980 (1980)
Defunct	July 2, 2023 (2023-07-02)
Fate	Bankrupt
Headquarters	New Jersey , United States
Key people	Ashleigh Palmer (CEO) Gregory T. Mayes, Esq. (Vice President) Nozer Mehta (Vice President) Paul Shields (Vice President)
Products	Research and development of peptides for medical purposes
Number of employees	53 (2020)
Website	www.unigene.com [dead link]

The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.^[3][4]

Unigene filed for Chapter 7 bankruptcy on July 2, 2013 in the United States Bankruptcy Court of the District of New Jersey. The Chapter 7 case is being administered under case No. 13-24696.

See also

• UgMicroSatdb